Navigation Links
Beckman Coulter Pending Acquisition of Olympus Diagnostics Systems Passes Milestone with U.S. Regulatory Approval
Date:5/13/2009

ORANGE COUNTY, Calif., May 13 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical testing, today announced that the Federal Trade Commission has terminated its review under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, of the company's pending acquisition of Olympus Corporation's lab-based diagnostics business.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

As previously announced on February 27, 2009, Beckman Coulter and Olympus announced that they had entered into a definitive agreement under which Beckman Coulter will acquire the diagnostic systems portion of Olympus' Life Sciences business for approximately USD $780 million.

This transaction is expected to close in the third quarter of 2009 and is subject to certain government approvals outside the United States, the negotiation of certain ancillary agreements, the delivery of and agreement to disclosure schedules and transition arrangements as well as other customary conditions.

About Beckman Coulter

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies, (including reagent test kits), service and operating-type lease payments, represent about 78% of the company's 2008 revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.

    Contacts:   Investor Relations
                Cynthia Skoglund
                (714) 773-7620

                Media Relations
                Mary Luthy
                (714) 773-7964


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
2. Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years
3. Beckman Coulter to Present at the Credit Suisse Global Healthcare Conference
4. Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako
5. Beckman Coulter to Present at the 2007 RBC Capital Markets Healthcare Conference
6. Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
7. Beckman Coulter Announces First Quarter 2008 Earnings to be Released on Wednesday, April 30, 2008, Before Market Opens
8. Beckman Coulter to Present at the Morgan Stanley Global Healthcare Unplugged Conference
9. Beckman Coulter Announces Third Quarter 2008 Results
10. Beckman Coulter to Present at Upcoming Healthcare Conferences
11. Beckman Coulter Announces First in Series of Flow Cytometry Product Introductions for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi ... patients who do not do their research and undergo cosmetic dermatology treatments from unqualified ... midst of a renaissance and every other month a new treatment or device is ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with ... , Over the last 60 years, studies have shown that single electrode ...
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to gain ... of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser Resurfacing ... age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or textural ...
(Date:12/2/2016)... ... 02, 2016 , ... Lori G. Cohen and Sara K. ... at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference , ... of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. 5, 2016 ... treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete ... better safety and tolerability profile of ropeginterferon alfa-2b versus HU ... and the ongoing long-term follow-up trial CONTINUATION-PV to obtain European ... intends to present this data to the FDA as it ...
(Date:12/4/2016)... Attorney General of Louisiana , Charles ... firm of Kahn Swick & Foti, LLC ("KSF"), announces that ... LCI ). On November 3, ... in Generic-Drug Probe to Be Filed by Year-End," which reported ... two years ago, now spans more than a dozen companies," ...
Breaking Medicine Technology: